Month: September 2023

  Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia AALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment to delivering innovation and a paradigm shift in the hemophilia treatment landscapeParis, September 25, 2023. The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is indicated for control of bleeding tendency in patients with hemophilia A (factor VIII deficiency). ALTUVIIIO was also recently approved by the Taiwan Food and Drug Administration for...

Ageas completes the sale of its French Life Insurance activities Ageas announces today that all regulatory approvals regarding the sale of its French life insurance, savings and pension business to La Mutuelle Epargne Retraite Prévoyance Carac (“Carac”) have been obtained and that the transaction has been completed. Ageas’s French Life and Pension activities consist of Ageas France, Ageas Retraite, Ageas Patrimoine and Sicavonline.Carac is a mutual operating in the domain of savings, protection and pension business in France. The operation will increase the liquidity of the Group by approximately EUR 185 million, and positively impact the Group’s Solvency II Pillar II ratio by 9% based on the position as at the end of June 2023.    Ageas is a listed international insurance Group with a heritage spanning almost 200 years. It offers Retail...

Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Deliveries will commence immediately. Dipal Patel, Chief Commercial Officer of Valneva commented, “We are excited to continue our long-term relationship with the DoD. The U.S. military has trusted IXIARO® for over ten years to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially...

Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera® in combination with long-acting octreotide, versus high-dose long-acting octreotide alone1,2Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful benefit in a first line setting1Findings to be presented at an upcoming medical meeting and discussed with regulatory authorities, with submissions to followNovartis is investigating a broad portfolio of RLTs, exploring their treatment potential in a range of advanced cancers beyond prostate and GEP-NET, including lung, breast, pancreatic and colon. The company...

Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023 Sandoz to be included in key Swiss market indices Investment grade credit rating for Sandoz confirmed: Moody’s, Baa2; S&P, BBB Debt financing of USD 3.75 billion (in various currencies) secured for Sandoz, supported by USD 1.25 billion revolving credit facility Spin-off to be completed by way of a 1:5 distribution of Sandoz shares to Novartis shareholders and Sandoz ADRs to Novartis ADR holdersBasel, September 25, 2023 — Novartis today confirmed plans for the 100% Spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023. This follows the previously announced Novartis shareholder approval for the Spin-off of Sandoz,...

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI® Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril*) and insoluble forms of Aβ. LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline...

Figure 1Olaroz Project LocationFigure 2Production Wellfield Pumping and Extracted Lithium in Brine to ponds (August 2013 to June 2023)Figure 3Location map of Measured, Indicated and Inferred Lithium Mineral ResourcesFigure 4Geological model of the Olaroz salar looking north through the northern part of the basinFigure 5Olaroz production well locationsFigure 6Lithium grades (mg/L) at 100 m (left) and 250 m below surface (right)Figure 7Resource blocks in lithium mg/l, showing the salar edge (red), alluvial zone (green) in the south and the muddy marginal zone outline (between red and blue outlines)Figure 8NPV Sensitivity AnalysisBRISBANE, Australia, Sept. 25, 2023 (GLOBE NEWSWIRE) — Allkem Limited (ASX|TSX: AKE) (“Allkem” or “the Company”) is pleased to announce...

Figure 1Sal de Vida project locationFigure 2Registered pumping and extracted lithium from the Stage 1 eastern wellfieldFigure 3Location map of Measured, Indicated and Inferred Lithium Mineral ResourcesFigure 4Sal de Vida Simplified Process Flow DiagramFigure 5Site layout for Stage 1 (blue) and Stage 2 expansion (green)Figure 6NPV Sensitivity AnalysisDrill hole information tableDrill hole information tableLocation map of exploration boreholesLocation map of exploration boreholesHydrogeological Cross-Section Locations (Plan View)Hydrogeological Cross-Section Locations (Plan View)Hydrogeological Cross-Section A-A’Hydrogeological Cross-Section A-A’Hydrogeological Cross-Section B-B’Hydrogeological Cross-Section B-B’Hydrogeological...